Jefferies Maintains Buy on Amarin

Jefferies is out with its report today on Amarin AMRN, maintaining Buy. In a note to clients, Jefferies writes, "The National Heart, Lung, and Blood Institute announced discontinuation of the AIM-HIGH trial, concluding that niacin with statin would not show benefit over statin alone in reducing cardiovascular-related complications. We continue to believe in a multi-billion market opportunity for AMR101, and AMRN remains one of our top biotech picks." Jefferies maintains a $25 PT on AMRN. Shares of AMRN closed Thursday at $19.13.